StockIQpro
NASDAQ:CAPR

Capricor Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Capricor Therapeutics, Inc.'s revenue fell 100.0% in fiscal 2025 to $0. Free cash flow was −$72.7M, and the diluted share count rose 32.0%.Summary generated from Capricor Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 17, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$0
Revenue growth−100.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−46.6%
Debt / equityn/a
Free cash flow−$72.7M
FCF marginn/a
Share count change+32.0%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue0325220
Operating income−21−30−24−43−108
Net income−20−29−22−40−105
Free cash flow−183−27−41−73

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations